Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).
Related Content:
Bioengineered cornea can restore sight to the blind and visually impaired
Retina may provide clues to the severity of multiple sclerosis
Connecticut ophthalmologist pleads guilty in health care fraud scheme
